期刊文献+

雷帕霉素洗脱支架治疗左主干病变冠心病患者的临床疗效 被引量:1

下载PDF
导出
摘要 目的分析雷帕霉素洗脱支架治疗左主干病变冠心病患者的临床疗效。方法 68例左主干病变冠心病患者,随机分为实验组和对照组,各34例。对照组患者接受金属裸支架介入治疗,实验组患者接受雷帕霉素洗脱支架介入治疗。术后随访1年,对比两组患者即刻成功率、心血管事件发生率、支架内再狭窄发生率。结果两组介入治疗即刻成功率均为100.00%,差异无统计学意义(P>0.05)。随访期间实验组心血管事件发生率、支架内再狭窄发生率均明显低于对照组,差异有统计学意义(P<0.05)。结论采用雷帕霉素洗脱支架治疗左主干病变冠心病效果满意,可降低心血管不良事件和支架内再狭窄的风险,值得在临床推广应用。
作者 袁超 吴婕
出处 《中国实用医药》 2015年第24期170-171,共2页 China Practical Medicine
  • 相关文献

参考文献6

二级参考文献57

  • 1于波.2011年冠心病介入治疗新进展[J].中国医学前沿杂志(电子版),2012,4(2):28-30. 被引量:9
  • 2ZHANG Qi ZHANG Rui-yan ZHANG Jian-sheng HU Jian YANG Zhen-kun NI Jun FANG Yue-hua ZHANG Xian SHEN Wei-feng.One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease[J].Chinese Medical Journal,2006(2):165-168. 被引量:23
  • 3Virmani R,Guagliumi G,Farb A,et al.Localized hypersensi-tivity and late coronary thrombosis secondary to a sirolimus-eluting stent:Should we be cautious?[J].Circulation,2004,109(6):701-705.
  • 4Brunner La,Rocca HP,Kaiser C,et al.Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent Kosten Effektivitats Trial (BASKET):an 18-month analysis[J].Lancet,2007,370 (9598):1552-1559.
  • 5Moses JW,Leon MB,Popma JJ,et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery[J].N Engl J Med,2003,349(14):1315-1323.
  • 6Grines CL,Bonow RO,Casey DE,et al.Prevention of prema-ture discontinuation of dual antiplatelet therapy in patients with coronary artery stents.a science advisory from the American Heart Association,American College of Cardiology,Society for Cardiovascular Angiography and Interventions,American College of Surgeons,and American Dental Association,with representation from the American College of Physicians[J].Circulation,2007,13,115(6):813-818.
  • 7STONE G W, ELLIS S G, CANNON L, et al. Comparison of a polymer based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial[J]. JAMA,2005,294 : 1215-1223.
  • 8PFISTERER M, BRUNNER-LA ROCCA H P, BUSER P T, et al. Late clinical events after elopi- dogrel discontinuation may limit the benefit of drugeluting stents: an observational study of drug-eluting versus bare-metal stents [J]. J Am Coll Cardiol, 2006,48 : 2584-2591.
  • 9WESSELY R, HAUSLEITER J, MICHAELIS C, et al. Inhibition of neointima formation by a novel drugeluting stent system that allows for doseadjustable, multiple, and on-site stent coating[J]. Arterioscler Thromb Vasc Biol,2005,251748-753.
  • 10BUSZMAN P, TRZNADEL S, MILEWSKI K, et al. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: a prospective multicenter registry[J]. Catheter Cardiovasc Interv,2008,71 : 51-57.

共引文献15

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部